Skip to main content

Advertisement

SpringerLink
Log in

Laparoscopic Peritoneal Cytology: Can it Affect Decision-Making for Neoadjuvant Treatment of Gastric Cancer?

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15(4):956–60.

    Article  PubMed  Google Scholar 

  2. Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9(9):828–30.

    Article  PubMed  Google Scholar 

  3. Badgwell B, Cormier JN, Krishnan S, Yao J, Staerkel GA, Lupo PJ, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008;15(10):2684–91.

    Article  PubMed  Google Scholar 

  4. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 2007;6(3):308–12.

    Article  PubMed  CAS  Google Scholar 

  5. Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol. 2007;14:2691–5.

    Article  PubMed  Google Scholar 

  6. Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol. 2004;11:127–129.

    Article  PubMed  Google Scholar 

  7. Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006;6:931–9.

    Article  PubMed  Google Scholar 

  8. Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol. 2002; 9: 220–1.

    Article  PubMed  Google Scholar 

  9. Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008; 247(4): 714–5.

    Article  PubMed  Google Scholar 

  10. Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(15):1555–6; author reply 1556.

    Article  PubMed  CAS  Google Scholar 

  11. Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15(1):21–33.

    Article  PubMed  Google Scholar 

  12. Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol. 2008;86:139–141.

    Article  PubMed  Google Scholar 

  13. Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. 2004;11(12):1030–4.

    Article  PubMed  Google Scholar 

  14. Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther. 2005;5(4):737–45.

    Article  PubMed  Google Scholar 

  15. Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;358(15):1635.

    Google Scholar 

  16. Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197.

    Article  PubMed  CAS  Google Scholar 

  17. Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8(5):587–97.

    Article  PubMed  Google Scholar 

  18. Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 2008;26(26):4360–1.

    Article  PubMed  Google Scholar 

  19. Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet. 2008;40(6):730–40.

    Article  PubMed  CAS  Google Scholar 

  20. Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008;8(1):29–39.

    Article  PubMed  CAS  Google Scholar 

  21. Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol. 2007;4(10):578–90.

    Article  PubMed  CAS  Google Scholar 

  22. Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol. 2008 [Epub ahead of print] DOI: 10.1245/s10434-008-0109-6.

  23. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. for Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.

    Google Scholar 

  24. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 1998;123(5):573–8.

    Article  PubMed  CAS  Google Scholar 

  25. Roukos DH. Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn. 2009;9(1):1–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Athens University, Athens, Greece

    T. Liakakos MD

  2. 2nd Department of Surgery, Democritus University of Thrace, Komotini, Greece

    A. Polychronidis MD

  3. 3rd Department of Surgery, University of Athens, Athens, Greece

    D. Bistarakis, K. Kopanakis & A. Macheras MD

Authors
  1. T. Liakakos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Polychronidis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Bistarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Kopanakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Macheras MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Liakakos MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liakakos, T., Polychronidis, A., Bistarakis, D. et al. Laparoscopic Peritoneal Cytology: Can it Affect Decision-Making for Neoadjuvant Treatment of Gastric Cancer?. Ann Surg Oncol 16, 1072–1073 (2009). https://doi.org/10.1245/s10434-008-0301-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-008-0301-8

Keywords

Search

Navigation